Project Number 1R44NS127671-01 Agency/Funding Organization NINDS Funding Year 2022 View Full Project Details for Phase 2 Enabling Studies of a Candidate Drug Therapy (T3D-959) Regulating Neurometabolism for the Treatment of Huntington's Disease Research Categorization Primary Disease / Condition Multiple Dementias CADRO Category C. Translational Research and Clinical Interventions 7. Early-stage Clinical Drug Development (Phase I and II Clinical Trials) j. Metabolism and Bioenergetics Researcher and Organization Principal Investigator DIDSBURY, JOHN Principal Investigator First Name JOHN Principal Investigator Last Name DIDSBURY Awardee Organization T3D THERAPEUTICS, INC. Awardee State North Carolina Contact PI Country United States Project Detail Funding Opportunity Announcement PA-21-259: PHS 2021-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed) FY Overall Cost $1,088,768 Funding Organization Agency/Funding Organization NINDS Funding Organization Country United States Program Official GILCHRIST, FLOY ANNETTE
